Drugs / Probio-M9
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07458529 | Feb 2026 → May 2027 expected | rectum adenocarcinoma | Seventh Medical Center of PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Probio-M9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07458529 ↗ |
| Route | Oral | “Probio-M9 is administered orally” NCT07458529 ↗ |